Novartis
enlisted the help of Danish drug discovery company
Nuevolution to identify small molecule leads against specific drug targets. Nuevolution will use its fragment-based drug screening platform called Chemetics®. The company says this technology combines proven wet chemistry and molecular biology to allow the rapid synthesis and selection of ligands from potentially billions of drug-like compounds in a single test tube. The companies will work together to carry out hit-to-lead optimization.